17th May 2012
Biomarkers identifying biological and physiological entities associated with disease are taking an increasingly important place at the tables of drug discovery and personalised medicine.
Their discovery in biosamples requires the combined use of genomics, proteomics and bioinformatics platforms. Whilst for their application, robust techniques combining exquisite sensitivity and specificity must be developed. This conference is focused on technologies that are driving advances in this area and their application at gene and expression level in solid and fluid biosamples. As such this conference is targeted to provide leading edge information to researchers within the academic, biotechnology and pharmaceutical sectors.
We include a panel session in this event, so that delegates can discuss their work directly with a panel of experts.
This event has CPD accreditation
Begin with biomarkers
Dr Peter H Bach, Director: BioPharmaLogic LLC, Cambridge.
Biomarkers are key to drug development and personalised medicine. The identification of the “right” fit-for-purpose biomarker is complex and resource intensive. Small companies have modest potentials to implement a biomarker strategy, but can still ensure that they build their development programmes around potential biomarkers. A biomarkers strategy should be a core to the development of each molecule, and not a bolt on addition to clinical development. If undertaken as part of discovery-development transition there is a potential to help shape the assessment of possible biomarkers as part of nonclinical development so that they are credible when needed.
DNA and RNA biomarker demonstration in solid tissues
Dr Tony Warford, Warford Technology Ltd, Newmarket, Suffolk, UK
Tissue donated from surgical procedures represents an important resource for biomarker identification. In ideal circumstances ‘fresh’ or frozen tissue will provide high quality DNA and RNA for analysis in situ or after extraction. However, most samples are held in the vast repositories of formalin fixed paraffin wax embedded (FFPE) tissues. In these preparations nucleic acids are degraded, principally through the fixation process. Practically this means that extraction methods have to be refined, amplicons are size limited and the possibility of the generation of spurious gene signatures needs to be considered. However, in spite of these limitations FFPE preparations provide very valuable information for the development and assessment of nucleic acid based biomarkers.
The Development Of Robust Technically Qualified Immunohistochemistry based Feasibility Assays
Neil Gray, Team Leader, Molecular Pathology group, AstraZeneca R&D Oncology iMed
Identification and quantification of cancer biomarkers using liquid chromatography-mass spectrometry
Dr David J. Britton, Proteome Sciences plc, Institute of Psychiatry, London
Liquid chromatography-mass spectrometry based proteomics can identify and quantify a multitude of proteins and post translational modifications from many different sample types (cell culture, tissue, plasma, etc). We have used this technology to identify new biomarkers and developed quantitative assays to measure the abundance of known biomarkers.
Expected Number of Attendees
View Conference Website: Biomarker discovery: Driving technologies
Price of Attendance
The Penridge Suite
470 Bowes Road